Elexacaftor tezacaftor ivacaftor therapy alters plasma sphingolipid profiles in people with cystic fibrosis
D. Westhölter (Essen, Germany), F. Schumacher (Berlin, Germany), N. Wülfinghoff (Essen, Germany), S. Sutharsan (Essen, Germany), S. Strassburg (Essen, Germany), B. Kleuser (Berlin, Germany), P. Horn (Essen, Germany), S. Reuter (Essen, Germany), E. Gulbins (Essen, Germany), C. Taube (Essen, Germany), M. Welsner (Essen, Germany)
Source: International Congress 2022 – Advances in cystic fibrosis research
Session: Advances in cystic fibrosis research
Session type: Oral Presentation
Number: 2920
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Westhölter (Essen, Germany), F. Schumacher (Berlin, Germany), N. Wülfinghoff (Essen, Germany), S. Sutharsan (Essen, Germany), S. Strassburg (Essen, Germany), B. Kleuser (Berlin, Germany), P. Horn (Essen, Germany), S. Reuter (Essen, Germany), E. Gulbins (Essen, Germany), C. Taube (Essen, Germany), M. Welsner (Essen, Germany). Elexacaftor tezacaftor ivacaftor therapy alters plasma sphingolipid profiles in people with cystic fibrosis. 2920
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|